There were 1,715 press releases posted in the last 24 hours and 402,041 in the last 365 days.

Giant Cell Arteritis Market is Predicted to Exhibit Rapid Growth During the Forecast Period (2024-2034) | DelveInsight

Giant Cell Arteritis Market

Giant Cell Arteritis Market

DelveInsight’s Giant Cell Arteritis Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, April 2, 2024 /EINPresswire.com/ --
The Giant Cell Arteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Giant Cell Arteritis pipeline products will significantly revolutionize the Giant Cell Arteritis market dynamics.

DelveInsight’s “Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Giant Cell Arteritis, historical and forecasted epidemiology as well as the Giant Cell Arteritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Giant Cell Arteritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Giant Cell Arteritis Market Forecast

Some of the key facts of the Giant Cell Arteritis Market Report:
The Giant Cell Arteritis market size was valued approximately USD 960 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In the United States, the age group of 80-89 years old had the highest incidence of Giant Cell Arteritis (GCA) cases reported in 2023.
In a study conducted by Tedeschi et al. (2022) using a US health insurance database and involving 734 Medicare patients, it was found that over 85% of patients were prescribed prednisone at a dose of ≥60mg per day at the index date, while less than 10% of patients were prescribed tocilizumab.
As per research conducted by Castañeda and colleagues (2022), it was observed in Spain that Giant Cell Arteritis (GCA) predominantly impacts individuals aged 50 years and above, with a prevalence rate of 30.4 per 100,000 population.
In 2023, regarding the distribution of Giant Cell Arteritis (GCA) cases by subtype, classic cranial GCA exhibited a slightly higher prevalence compared to extra-cranial GCA across the seven major markets (7MM).
Key Giant Cell Arteritis Companies: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others
Key Giant Cell Arteritis Therapies: Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others
In 2023, it was noted that the age group of patients over 80 years old had the highest number of reported cases of Giant Cell Arteritis (GCA) across the seven major markets (7MM).
The Giant Cell Arteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Giant Cell Arteritis pipeline products will significantly revolutionize the Giant Cell Arteritis market dynamics.

Giant Cell Arteritis Overview
Large and middle-sized blood vessels are affected by Giant Cell Arteritis (GCA), also known as temporal arteritis, a vasculitis that is more common in those over 50 and has a tendency to impact cranial arteries that originate from the carotid artery.

Get a Free sample for the Giant Cell Arteritis Market Report:
https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Giant Cell Arteritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Giant Cell Arteritis Epidemiology Segmentation:
The Giant Cell Arteritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Giant Cell Arteritis
Prevalent Cases of Giant Cell Arteritis by severity
Gender-specific Prevalence of Giant Cell Arteritis
Diagnosed Cases of Episodic and Chronic Giant Cell Arteritis

Download the report to understand which factors are driving Giant Cell Arteritis epidemiology trends @ Giant Cell Arteritis Epidemiology Forecast

Giant Cell Arteritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Giant Cell Arteritis market or expected to get launched during the study period. The analysis covers Giant Cell Arteritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Giant Cell Arteritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Giant Cell Arteritis Therapies and Key Companies
Rinvoq(upadacitinib): AbbVie
Cosentyx (secukinumab): Novartis
KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals
Tremfya(guselkumab): Johnson & Johnson/ MorphoSys AG
Baricitinib: Eli Lilly and Company
Tocilizumab + Glucocorticoids (GCs): Roche Pharma
Secukinumab: Novartis
Guselkumab: Janssen Research & Development
Tocilizumab: Hoffmann-La Roche
adalimumab: Abbott
Upadacitinib: AbbVie

Giant Cell Arteritis Market Strengths
Improved and clear treatment and diagnostic guidelines has led the patients and practitioners to clearly diagnose and treat the patients accurately.
While glucocorticoids remain the primary treatment, there is ongoing research into alternative and adjunctive therapies, such as biologic agents like tocilizumab. This diversification in treatment options provides more tailored approaches for patients, considering factors like side effects and individual response.

Giant Cell Arteritis Market Opportunities
The development of targeted biologic therapies offers a significant opportunity for improving treatment outcomes in GCA. Biologics, such as interleukin-6 (IL-6) inhibitors like tocilizumab, have shown promise in clinical trials. Further research and development in this area can lead to more effective and targeted treatments.
The introduction of biosimilars for existing therapies can increase competition, potentially reducing treatment costs and improving accessibility for patients.

Scope of the Giant Cell Arteritis Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Giant Cell Arteritis Companies: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others
Key Giant Cell Arteritis Therapies: Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others
Giant Cell Arteritis Therapeutic Assessment: Giant Cell Arteritis current marketed and Giant Cell Arteritis emerging therapies
Giant Cell Arteritis Market Dynamics: Giant Cell Arteritis market drivers and Giant Cell Arteritis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Giant Cell Arteritis Unmet Needs, KOL’s views, Analyst’s views, Giant Cell Arteritis Market Access and Reimbursement

To know more about Giant Cell Arteritis companies working in the treatment market, visit @ Giant Cell Arteritis Clinical Trials and Therapeutic Assessment

Table of Contents
1. Giant Cell Arteritis Market Report Introduction
2. Executive Summary for Giant Cell Arteritis
3. SWOT analysis of Giant Cell Arteritis
4. Giant Cell Arteritis Patient Share (%) Overview at a Glance
5. Giant Cell Arteritis Market Overview at a Glance
6. Giant Cell Arteritis Disease Background and Overview
7. Giant Cell Arteritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Giant Cell Arteritis
9. Giant Cell Arteritis Current Treatment and Medical Practices
10. Giant Cell Arteritis Unmet Needs
11. Giant Cell Arteritis Emerging Therapies
12. Giant Cell Arteritis Market Outlook
13. Country-Wise Giant Cell Arteritis Market Analysis (2020–2034)
14. Giant Cell Arteritis Market Access and Reimbursement of Therapies
15. Giant Cell Arteritis Market Drivers
16. Giant Cell Arteritis Market Barriers
17. Giant Cell Arteritis Appendix
18. Giant Cell Arteritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here